Drug company halts development of osteoporosis treatment
08 Sep 2016
An osteoporosis drug which was being developed by pharmaceutical company Merck will not now become available after an independent analysis showed the treatment was associated with an increased risk of strokes.
While the drug, odanacatib, was found to reduce the risk of fractures, the increased risk of stroke means development of the treatment will now be abandoned.
Professor Neil Gittoes, Consultant & Honorary Professor of Endocrinology at University Hospitals Birmingham NHS Foundation Trust and a National Osteoporosis Society Trustee, said:
“It is a great disappointment that a potentially useful treatment that could have expanded the choices for people affected by osteoporosis will now not become available. Despite its beneficial effect in preventing fractures, we have to, of course, recognise that patient safety will always be paramount.”
There’s more information on the way drugs are developed on the Drug treatments for osteoporosis page on our website.